Kornimate/medical-research-clean huggingface dataset:
a study of intravenous acetaminophen for small bowel obstruction

Conditions: Small Bowel Obstruction

Summary: the purpose of this study is to compare iv acetaminophen for pain control to the usual care with opioids in patients admitted for small bowel obstruction.

the primary aim of this study is to assess the feasibility of conducting a randomized trial involving intravenous acetaminophen for pain control compared to usual care with opioids in patients admitted for small bowel obstruction and to summarize pain scores up to 72 hours after treatment. patients presented and diagnosed with small bowel obstruction (sbo) will be screened for eligibility and will be offered participation in this study. patients admitted for sbo for medical management with pain on admission will be eligible to participate in study. this will include patients with malignant and nonmalignant sbo. participants will be randomly assigned into one of two groups, either the treatment group which receive iv acetaminophen or the usual care group which will receive intravenous morphine or hydromorphone as needed for pain control. a nasogastric (ng) tube will be placed when it is indicated, if patient is having significant nausea or vomiting. pain scores will be followed as usual pain management assessment and reported in the medical record. once sbo is resolved (usually 3 days after admission), active study participation will end. participants may be followed via their medical record up to 30 days after discharge.

Eligibility criteria:
inclusion criteria: * small bowel obstruction diagnosed by radiographic study; and * abdominal pain on admission. * nothing per mouth diet. * the ability to give appropriate consent or have an appropriate representative available to do so. exclusion criteria: * known liver failure or cirrhosis. * acetaminophen toxicity on admission. * known acetaminophen allergy. * alcohol intoxication on admission. * history of substance abuse. * creatinine clearance \ 2). * liver transplant recipients. * ileus on admission. * admitted for surgical intervention for sbo. * admitted for venting gastric tube placement. * on chronic opioid therapy (defined as use of opioid on daily or near daily basis within previous 45 days (both long acting and short acting). * presentation without abdominal pain on admission. * already hospitalized for other reasons and develop sbo while at the hospital. * pregnant women. * unable to provide informed consent.
comparison between limited driving pressure ventilation and conventional mechanical ventilation strategies in medical intensive care patients with acute respiratory failure

Conditions: on Invasive Mechanical Ventilation; ARDS; Respiratory Failure

Summary: background an appropriated mechanical ventilator setting for acute respiratory failure results of ventilator associated lung injury. limited driving pressure and low tidal volume ventilation strategies show benefits decreasing mortality in acute respiratory distress syndrome, but there are no data in simple acute respiratory failure.

background an appropriated mechanical ventilator setting for acute respiratory failure results of ventilator associated lung injury. limited driving pressure and low tidal volume ventilation strategies show benefits decreasing mortality in acute respiratory distress syndrome, but there are no data in simple acute respiratory failure. to compare lung injury score (lis, murray score) after invasive mechanical ventilation 7 days between groups of limited driving pressure ventilation versus low tidal volume ventilation strategies.

Eligibility criteria:
inclusion criteria: * age ≥ 18 year old micu patient * on invasive mechanical ventilator less than 24 hr. before randomization exclusion criteria: * suspected death within 48 hr. after randomization * patients with tracheostomy tube * pregnancy * do not attempt resuscitation order * patient with ecmo before randomization

Keywords: limited driving pressure low tidal volume lung injury score
integrating a health information technology system for primary and secondary cervical cancer prevention

Conditions: Human Papilloma Virus; Cervical Cancer; Human Papillomavirus Infection; Oropharyngeal Cancer; Vaginal Cancer; Vulvar Cancer; Anal Cancer; Penile Cancer

Summary: the project aims to increase hpv vaccination and cervical cancer screening through a web-based mobile health education program called, wheel of wellness (wow) and a brief negotiated interview (bni). the in-person bni and wow system will provide educational resources for participants and their families to learn more about hpv vaccination and cervical cancer screening.

wow will be tailored to the participant and will be based on the participant's cancer screening and hpv vaccine health needs; it will then send custom text messages based their concerns and will remind them to schedule and attend their doctor's appointment. the researchers will conduct a single armed proof of concept where the participants will be actively using wow. the in-person bni will empower participants to have positive behavioral changes in regards to their health by giving them appropriate health information as well as answering their questions and concerns about cervical cancer prevention and screening.

Eligibility criteria:
inclusion criteria: 1. parent/guardian with a child between the ages of 9 to 17 who receives primary care at one of the participating sites and their male child. 2. parent/guardian with a male child who provides consent to have child's hpv vaccination status checked in emr. 3. parent/guardian with a male child who has neither initiated the hpv vaccine nor completed the series 4. parent/guardian and male child with the ability to read and write in english. 5. parent/guardian and male child have access to a smartphone. exclusion criteria: 1. parent/guardian's eligible child is pregnant. 2. parent/guardian's has begun or completed the hpv series. 3. parent/guardian, in the opinion of the clinical staff, is cognitively impaired and unable to give informed consent.

Keywords: hpv vaccinaton cervical cancer screening web-based mobile health education brief negotiated interview (bni
effect of rhbnp on cmd in patients with stemi after ppci

Conditions: STEMI

Summary: the target population of this interventional study was stemi patients. primary discussion: early rhbnp reduces microcirculation obstruction in stemi patients undergoing primary pci

direct percutaneous coronary intervention is the preferred reperfusion strategy for acute st-segment elevation myocardial infarction. during the opening of infarct-related vessels, 5%-50% of patients showed slow flow or no reflow and other coronary microcirculation dysfunction, which aggravated myocardial injury and increased the incidence and mortality of heart failure. studies have shown that recombinant human brain natriuretic peptide (rhbnp) can reduce reperfusion injury and reduce myocardial infarction area cmd. prolonged ischemia leads to rapid depletion of intracellular atp and tissue metabolic acidosis. blood flow irrigation during reperfusion leads to decreased levels of atp precursors, calcium overload in mitochondria, release of a large number of inflammatory factors and oxygen free radicals, which can lead to injury or death of myocardial and endothelial cells. rhbnp can enhance the activity of antioxidant enzymes, reduce the irreversible oxidative damage caused by free radicals to myocardium, reduce the myocardial infarction area during ischemia reperfusion, and may reduce the reperfusion injury and protect the viable myocardium.

Eligibility criteria:
inclusion criteria: * stemi * ppci within 24 hours of symptom onset * target vessel qfr-mr\>250mm hg\*s/m exclusion criteria: * claustrophobia * postoperative timi grade 0-1 * pregnancy
neuromuscular electrical stimulation in pulmonary arterial hypertension

Conditions: Pulmonary Arterial Hypertension

Summary: this study aimed to investigate the effects of neuromuscular electrical stimulation on peripheral muscles and other physical and psychosocial variables in patients with pulmonary arterial hypertension. this study was designed as an assessor-blind randomized controlled trial. thirty-one patients with pulmonary arterial hypertension will be recruited. the participants will randomly divided two parallel groups as treatment and control. for the treatment group, neuromuscular electrical stimulation will be applied to the bilateral deltoid and quadriceps femoris muscles with 50 hz for 3 days/week, 8 weeks. control group will not be received any additional treatment, just given healthy life recommendations such as walking. the participants will be assessed before and after the treatment by a blind assessor to the group allocation. the outcome measure will be assessments of the upper and lower limb muscle strength, respiratory muscle strength, muscle cross-sectional area and thickness, pulse wave velocity, exercise capacity, walking speed, functional mobility and balance performances, balance confidence, fatigue perceptions, physical activity level, activities of daily living and quality of life.


Eligibility criteria:
inclusion criteria: * elevated pulmonary artery pressures measured by right heart catheterization * new york heart association class ii or iii * stabile pulmonary arterial hypertension-specific pharmaceutical therapy for 3 months exclusion criteria: * orthopaedic problems * significant restrictive or obstructive pulmonary disease * acute cor pulmonale.
axillary reverse mapping

Conditions: Breast Cancer

Summary: it has been hypothesized that the proximity of the anatomic locations of the arm lymphatic drainage system to the breast lymphatic system in the axilla put the arm lymphatics at risk for disruption during a sentinel lymph node biopsy (slnb) and/or axillary lymph node dissection (alnd). therefore, mapping the drainage of the arm in addition to the drainage of the breast during the procedure would potentially decrease the incidence of arm lymphatic disruption and subsequent development of lymphedema while providing adequate axillary breast nodes needed for staging.

patients will receive an injection of 1.0 mci of technetium-99m sulfur colloid that will be injected into the sub-dermal subareolar aspect of the affected breast. on the day of surgery, if the radioactive sln cannot be located using the gamma probe prior to incision, lymphazurin or methylene blue dye will be used in the breast in the subareolar plexus at the discretion of the surgeon for assistance in identifying the sentinel nodes. this contingency, expected to occur \< 3% of the time, will be used since locating the sln for staging is of greater importance than the study. if radioactive isotope is sufficient to identify the sentinel node draining from the breast, then the blue dye will be injected dermally in the upper inner arm along the bicipital groove of the ipsilateral arm in order to locate the draining lymphatics from the arm. no more than 5cc of blue dye will be injected in any of the above mentioned scenarios. the site of all injections (radioactivity and/or blue dye) will be recorded.

Eligibility criteria:
inclusion criteria: * 18 - 100 years old * not pregnant or breastfeeding * diagnosis of breast cancer requiring ln evaluation for ipsilateral or contralateral breast or prophylactic mastectomy * willing participation after obtaining informed consent exclusion criteria: * \ 100 years of age * pregnant or breastfeeding * blue dye allergy * cosmetic allergy * history of primary lymphedema * prior breast augmentation

Keywords: sentinel lymph node biopsy axillary lymph node dissection prevention of lymphedema
evaluation and validation of social cognition battery to characterize schizophrenic patients functioning

Conditions: Schizophrenia

Summary: interventional, multicenter, and longitudinal study, of a cohort of patients with schizophrenia, evaluated on social cognition, neurocognition, symptoms, functioning with 12 months interval.

the main objective is evaluation and validation of social cognition battery, characterizing the psychometric properties (validity, sensitivity to change) measures in a cohort of schizophrenic patients. other objective is to demonstrate that the various components operating at t0 and t12 months of schizophrenic patients, as an external validator, are significantly explained by social cognition performance given the third known factors : neuropsychological, sociodemographic, disease course, and clinical status. search and model relationships between the measured variables.

Eligibility criteria:
inclusion criteria: * schizophrenia or schizoaffective disorder * age \> 18 years and \< 65 years * patient's state allows cognitive and neuropsychological assessment * affiliated to a social security system (beneficiary or legal). * informed consent signature (patients under guardianship may be included with written permission from their legal representative). exclusion criteria: * alcohol dependence or current toxic * electroconvulsivotherapy (less than 6 months) * serious head trauma (become unconscious), epilepsy or neurological disorder significant or evolutionary * invalidating and uncorrected visual disorder * invalidating and not paired hearing * actually hospitalized under constraint * patient not able to come to different evaluations, or who plan to change medical care in the following year

Keywords: schizophrenia
corkscrew technique: a novel modification in transurethral resection of large prostate (60-100 g) optimizing resection efficacy and safety: a double-blind randomized controlled trial

Conditions: TURP(Transurethral Resection of Prostate); BPH (Benign Prostatic Hyperplasia); Prostate

Summary: transurethral resection of the prostate (turp) is still the gold standard for surgical management of enlarged prostate. however, many techniques and minimally invasive procedures are now in the comparative track with bipolar resection as laser enucleation. multiple drawbacks of classic turp problems related to large prostate management as the retreatment after bipolar resection, another issue that prolonged operative time, loss of orientation during resection due to rotation of one of the 2 kissing lobe, bleeding of the 1st lobe resection side make the 2nd lobe resection harder and lengthier, median lobe resection or bladder neck resection is done at last to avoid sub-trigonal injury. however, due to median lobe obstruction, irrigation is poor during all the resection. length of learning curve, the modification of early median lobe resection carry the risk of sub-trigonal injury. so, this study is a trial to analyze the effect of new technique in resection of large prostate with good orientation and less time of operation.


Eligibility criteria:
inclusion criteria: * bph causing luts with prostate volume between 60 and 100 ml (either by trus or ct). * psa level below 4 ng/ml. * ipss score of 10 and above. exclusion criteria: * previous history of prostatic biopsy. * previous history of acute urinary retention.

Keywords: turp bph prostate blandy nesbit
efficacy and safety of endovenous radio frequency (evrf) for treatment of varicose veins in singapore

Conditions: Varicose Veins; Venous Reflux; Chronic Venous Insufficiency

Summary: the aim of this study is to report a collaborative, prospective singaporean experience using the endovenous radio frequency® (evrf®) from f care systems (belgian) for the treatment of primary great and short saphenous vein reflux.

the investigators wish to evaluate its safety, efficacy, and performance. although it has been shown to be safe and efficacious in its initial trials, these studies have been limited to generally a caucasian-based population, where the vein size, anatomy and distribution of venous incompetence can be different from their asian counterparts. the study will evaluate the technical, anatomical and clinical performance of evrf® performed on multiple truncal varicose veins, and without mandatory postoperative compression stockings of the gsv, ssv or aasv. the two primary endpoints for this evaluation are technical success at the time of the procedure, and anatomical success, reported as complete closure at 2-weeks, 3 months, 6 months and 12 months.

Eligibility criteria:
inclusion criteria: 1. age \>21 years, able to understand the requirements of the study and provide informed consent. 2. c2 - c5 varicose veins / cvi 3. symptomatic primarygsv, ssv or aasv incompetence, with reflux \>0.5 seconds on colour duplex, including one or more of the following symptoms: aching, throbbing, heaviness, fatigue, pruritus, night cramps, restlessness, generalized pain or discomfort, swelling. 4. patients who has gsv, ssv or aasv diameters of 3mm to 12mm in the standing position. exclusion criteria: 1. current dvt or history of dvt 2. recurrent varicose veins 3. pregnant patients 4. arterial disease (abpi\<0.8) 5. sepsis 6. patients who are unwilling to participate 7. inability or unwillingness to complete questionnaires 8. adverse reaction to sclerosant or cyanoacrylate 9. gsv, ssv or aasv severely tortuous 10. life expectancy \< 1 year 11. active treatment for malignancy other than non-melanoma skin cancer 12. current, regular use of systemic anticoagulation (e.g. warfarin, heparin) 13. daily use of narcotic analgesia or nsaids to control pain associated with venous disease

Keywords: endovenous ablation
transbronchial biopsy assisted by robot guidance in the evaluation of tumors of the lung

Conditions: Pulmonary Nodule; Lung Cancer

Summary: this study is designed to evaluate clinical safety and diagnostic accuracy of the robotic-assisted bronchoscopy with biopsy performed with the monarch™ endoscopy platform in a broad range of patients with pulmonary lesions.

despite technological advancements in guided bronchoscopy such as electromagnetic navigation bronchoscopy and radial probe endobronchial ultrasound, successful biopsy of peripheral pulmonary lesions remains a challenge due to a number of factors, one of which may be the ability to gain access to peripheral lesions due to the size and maneuverability of conventional bronchoscopes. the diagnostic yield of conventional bronchoscopic approaches for peripheral lesions remains suboptimal. a novel robotic assisted bronchoscopy procedure now exists for patients with lung nodules. this procedure is performed using the monarch™ platform (auris health, inc., redwood city, ca). this study is expected to enroll up to 1200 patients at up to 30 investigative sites.

Eligibility criteria:
inclusion criteria: 1. over 21 years of age; 2. capable and willing to give informed consent; 3. acceptable candidate for an elective, non-emergent bronchoscopic procedure; 4. lung lesions, 8 mm to 50 mm in size, requiring bronchoscopic diagnosis which were identified on thin slice ct scan within 28 days of the intended bronchoscopy exclusion criteria: 1. medical contraindication to bronchoscopy as assessed by the investigator 2. presence of uncorrectable bleeding disorders 3. medical devices interfering with electro-magnetic navigation, including but not limited to pacemaker 4. patients with the target lesion having endobronchial involvement seen on chest ct 5. lack fitness to undergo flexible bronchoscopy as determined by the bronchoscopist prior to procedure, 6. participation in any other clinical trial within 30 days of enrollment that would interfere with this study; 7. uncontrolled or irreversible coagulopathy; 8. female subjects who are pregnant or nursing at the time of the procedure or those of child-bearing potential refusing a pregnancy test prior to the procedure; 9. ct scan done greater than 28 days before the bronchoscopy procedure.

Keywords: bronchoscopy robotic bronchoscopy lung lesions peripheral lesions lung cancer monarch
intensive self-care on glycemic control in outpatients with type 2 diabetes mellitus: the diabetes care (d-care) study

Conditions: Diabetes Mellitus, Type 2; Cardiovascular Diseases; Diabetes Mellitus

Summary: type 2 diabetes mellitus (t2dm) leads to a high burden of morbidity and mortality, usually attributable to cardiovascular (cvd) causes. a major concern about the disease is that the success of the treatment is highly dependent on self-management, which very often incurs the necessity of behavior change. however, modifying such behaviors, usually linked to daily-life activities, is challenging. then, the investigators aimed to test the optimal self-management that could be achieved in a reasonable manner carried forward through the prochaska and diclemente behavior-changing strategy in a follow-up of 18 months, compared to usual care. our primary outcome is the between-group difference in hba1c (%) levels.


Eligibility criteria:
inclusion criteria: * outpatients diagnosed with type 2 diabetes mellitus - t2dm (hba1c % - ≥ 6.5%, or taking at least one oral hypoglycaemic agent, or medical diagnosis); * to be regularly assisted by the sistema único de saúde and to have been saw at least one year before randomization; * readiness for behavior-changing within the pre-action stages: pre-contemplation, contemplation and preparation; * t2dm patient of challenging handling (e.g., frequent hypoglycaemic seizures, cardiovascular disease (cvd), etc.); exclusion criteria: * pregnant women; * people living with hiv/aids; * t2dm patients taking erythropoietin, recent blood loss, recent blood transfusion and severe anaemia; * t2dm patients with cvd under non-optimized treatment; or those that made any cvd procedure; or cvd event (e.g., myocardial infarction) within three months before randomization; * t2dm patients with severe eye and retine disease; * patients participating in another study simultaneously; * patients living with others in the same place.

Keywords: self management behavior type 2 diabetes mellitus cardiovascular disease